



22 May 2024

Our Ref: RFI 57512

**Freedom of Information Act 2000
Information in Relation to Breast Cancer Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 3 April 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Medicine, Unscheduled Care and Cancer Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies, listed in Table 1.

A1. Please see Table 1 for number of patients treated for breast cancer with the listed therapies.

Table 1

Treatment	No. of Patients Treated
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	2
Abemaciclib + Fulvestrant	Nil
Alpelisib + Fulvestrant	Nil
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	Nil
Atezolizumab + Nab-paclitaxel/Paclitaxel	4
Capecitabine as a single agent	Nil
Eribulin as a single agent or in combination	2
Everolimus + Exemestane	Nil
Fulvestrant as a single agent	3
Lapatinib	Nil
Neratinib	Nil
Parp Inhibitors (Olaparib/Talazoparib)	Nil
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	6
Palbociclib + Fulvestrant	6
Pembrolizumab	3
Platinum (e.g. carboplatin or cisplatin) as a single agent	1
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	8
Ribociclib + Fulvestrant	Nil
Sacituzumab Govitecan	1
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	1
Taxane and/or Anthracycline in combination	Nil
Trastuzumab as a single agent or in combination	
Trastuzumab emtansine	5
Transtuzumab deruxtecan	1
Any other active systemic anti-cancer therapy	44

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

A2. Yes, the Trust participates in clinical trials for Breast Cancer. Please see Table 2 for the name of the trials and the number of patients taking part.

Table 2

Trial/Study	No. of Patients
Optima	5
Horizons	148
Poetic	20
Loris	1